Lower levels of high-density lipoprotein cholesterol on admission and a recurrence of ischemic stroke: A 12-month follow-up of the Fukuoka Stroke Registry

Journal of Stroke and Cerebrovascular Diseases

Volumn 21, Issue 7, 2012, Pages 561-568

  Kuwashiro, Takahiro ^a   Sugimori, Hiroshi ^a   Kamouchi, Masahiro ^a   Ago, Tetsuro ^a   Kitazono, Takanari ^a   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiotensin receptor blocker; high density lipoprotein; ischemic stroke; recurrence

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BRAIN ISCHEMIA; DATA BASE; DISEASE PREDISPOSITION; DISEASE REGISTRY; FEMALE; FOLLOW UP; GROUPS BY AGE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RECURRENT DISEASE; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT ADMISSION; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS;

EID: 84866696477     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2010.12.011     Document Type: Article

References (46)

1. T. Hillen, C. Coshall, and K. Tilling Cause of stroke recurrence is multifactorial: Patterns, risk factors, and outcomes of stroke recurrence in the South London Stroke Register Stroke 34 2003 1457 1463
2. G.J. Hankey Long-term outcome after ischaemic stroke/transient ischaemic attack Cerebrovasc Dis 16 Suppl 1 2003 14 19
3. M.S. Elkind Outcomes after stroke: Risk of recurrent ischemic stroke and other events Am J Med 122 Suppl 2009 S7 S13
4. G.W. Petty, R.D. Brown Jr., and J.P. Whisnant Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989 Neurology 50 1998 208 216
5. G.J. Hankey, K. Jamrozik, and R.J. Broadhurst Long-term risk of first recurrent stroke in the Perth Community Stroke Study Stroke 29 1998 2491 2500
6. P. Appelros, I. Nydevik, and M. Viitanen Poor outcome after first-ever stroke: Predictors for death, dependency, and recurrent stroke within the first year Stroke 34 2003 122 126
7. R.L. Sacco, T. Shi, and M.C. Zamanillo Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study Neurology 44 1994 626 634
8. G. Xu, X. Liu, and W. Wu Recurrence after ischemic stroke in Chinese patients: Impact of uncontrolled modifiable risk factors Cerebrovasc Dis 23 2007 117 120
9. K. Toyoda, Y. Okada, and S. Kobayashi Early recurrence of ischemic stroke in Japanese patients: The Japan standard stroke registry study Cerebrovasc Dis 24 2007 289 295
10. J.T. Moroney, E. Bagiella, and M.C. Paik Risk factors for early recurrence after ischemic stroke: The role of stroke syndrome and subtype Stroke 29 1998 2118 2124
11. J.A. Egido Benefits of modifying the predictive factors of stroke recurrence Cerebrovasc Dis 20 Suppl 2 2005 84 90
12. J.K. Lovett, A.J. Coull, and P.M. Rothwell Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies Neurology 62 2004 569 573
13. B.M. Psaty, M. Anderson, and R.A. Kronmal The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: The Cardiovascular Health Study J Am Geriatr Soc 52 2004 1639 1647
14. T. Imamura, Y. Doi, and H. Arima LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: The Hisayama study Stroke 40 2009 382 388
15. P. Amarenco, J. Bogousslavsky, and A. Callahan 3rd High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
16. P. Amarenco, L.B. Goldstein, and A. Callahan 3rd Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial Atherosclerosis 204 2009 515 520
17. C.W. Liou, T.Y. Tan, and T.K. Lin Metabolic syndrome and three of its components as risk factors for recurrent ischaemic stroke presenting as large-vessel infarction Eur J Neurol 15 2008 802 809
18. H.P. Adams Jr., B.H. Bendixen, and L.J. Kappelle Classification of subtype of acute ischemic stroke: Definitions for use in a multicenter clinical trial Stroke 24 1993 35 41
19. T. Teramoto, J. Sasaki, and H. Ueshima Diagnostic criteria for dyslipidemia. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese J Atheroscler Thromb 14 2007 155 158
20. S. Matsuo, E. Imai, and M. Horio Revised equations for estimated GFR from serum creatinine in Japan Am J Kidney Dis 53 2009 982 992
21. S.G. Wannamethee, A.G. Shaper, and S. Ebrahim HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men Stroke 31 2000 1882 1888
22. J.M. Leppälä, J. Virtamo, and R. Fogelholm Different risk factors for different stroke subtypes: Association of blood pressure, cholesterol, and antioxidants Stroke 30 1999 2535 2540
23. R.L. Sacco, R.T. Benson, and D.E. Kargman High-density lipoprotein cholesterol and ischemic stroke in the elderly: The Northern Manhattan Stroke Study JAMA 285 2001 2729 2735
24. J.D. Curb, R.D. Abbott, and B.L. Rodriguez High density lipoprotein cholesterol and the risk of stroke in elderly men: The Honolulu Heart Program Am J Epidemiol 160 2004 150 157
25. Y. Soyama, K. Miura, and Y. Morikawa High-density lipoprotein cholesterol and risk of stroke in Japanese men and women: The Oyabe Study Stroke 34 2003 863 868
26. T. Okamura, T. Hayakawa, and T. Kadowaki The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population Atherosclerosis 184 2006 143 150
27. H.D. White, R.J. Simes, and N.E. Anderson Pravastatin therapy and the risk of stroke N Engl J Med 343 2000 317 326
28. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group N Engl J Med 341 1999 410 418
29. N. Nakaya, T. Kita, and H. Mabuchi Large-scale cohort study on the relationship between serum lipid concentrations and risk of cerebrovascular disease under low-dose simvastatin in Japanese patients with hypercholesterolemia: Sub-analysis of the Japan Lipid Intervention Trial (J-LIT) Circ J 69 2005 1016 1021
30. R.L. Sacco, R. Adams, and G. Albers Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: Co-sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline Stroke 37 2006 577 617
31. H. Bloomfield Rubins, J. Davenport, and V. Babikian Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation 103 2001 2828 2833
32. N. Sanossian, J.L. Saver, and M. Navab High-density lipoprotein cholesterol: An emerging target for stroke treatment Stroke 38 2007 1104 1109
33. J.A. Berliner, and A.D. Watson A role for oxidized phospholipids in atherosclerosis N Engl J Med 353 2005 9 11
34. M. Navab, S.Y. Hama, and G.P. Hough A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids J Lipid Res 42 2001 1308 1317
35. P.K. Shah, S. Kaul, and J. Nilsson Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming, part I Circulation 104 2001 2376 2383
36. M. Viñals, J. Martínez-González, and J.J. Badimon HDL-induced prostacyclin release in smooth muscle cells is dependent on cyclooxygenase-2 (Cox-2) Arterioscler Thromb Vasc Biol 17 1997 3481 3488
37. M. Briel, I. Ferreira-Gonzalez, and J.J. You Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: Systematic review and meta-regression analysis BMJ 338 2009 b92
38. B. Dahlöf, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol Lancet 359 2002 995 1003
39. H. Lithell, L. Hansson, and I. Skoog The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial J Hypertens 21 2003 875 886
40. S. Mochizuki, B. Dahlöf, and M. Shimizu Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomised, open-label, blinded endpoint morbidity-mortality study Lancet 369 2007 1431 1439
41. J. Schrader, S. Lüders, and A. Kulschewski Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: Principal results of a prospective randomized controlled study (MOSES) Stroke 36 2005 1218 1226
42. S. Yusuf, H.C. Diener, and R.L. Sacco Telmisartan to prevent recurrent stroke and cardiovascular events N Engl J Med 359 2008 1225 1237
43. A.H. Madrid, M.G. Bueno, and J.M. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study Circulation 106 2002 331 336
44. A. Ducharme, K. Swedberg, and M.A. Pfeffer Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program Am Heart J 152 2006 86 92
45. R.E. Schmieder, S.E. Kjeldsen, and S. Julius Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial J Hypertens 26 2008 403 411
46. J. Burn, M. Dennis, and J. Bamford Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project Stroke 25 1994 333 337